Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 117
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00562224 | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients | ||
| NCT03359460 | Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome | ||
| NCT02315326 | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | ||
| NCT02142049 | Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma | ||
| NCT03088878 | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | ||
| NCT03207555 | Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) | ||
| NCT00473577 | Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients | ||
| NCT00102505 | A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) | ||
| NCT01704963 | A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms | ||
| NCT01722487 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | ||
| NCT00080041 | Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors | ||
| NCT00080054 | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | ||
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | ||
| NCT00724984 | Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma | ||
| NCT02436668 | Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) | ||
| NCT02272686 | Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma | ||
| NCT04450173 | Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | ||
| NCT02077166 | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | ||
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | ||
| NCT02604511 | Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing | ||
| NCT04694560 | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | ||
| NCT05963074 | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | ||
| NCT00849654 | Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma | ||
| NCT01744691 | A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion | ||
| NCT02518555 | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ||
| NCT01866033 | A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants | ||
| NCT02575300 | Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | ||
| NCT02195869 | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease | ||
| NCT00076401 | A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) | ||
| NCT01833039 | An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | ||
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib) | ||
| NCT02943473 | Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients | ||
| NCT01752426 | Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL | ||
| NCT01105247 | Safety of PCI-32765 in Chronic Lymphocytic Leukemia | ||
| NCT05431179 | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | ||
| NCT01779791 | A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma | ||
| NCT01855750 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | ||
| NCT03267186 | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | ||
| NCT01569750 | A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma | ||
| NCT01578707 | A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | ||
| NCT02582879 | informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia | ||
| NCT01325701 | Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | ||
| NCT03198026 | Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas | ||
| NCT02899078 | Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer | ||
| NCT03379428 | Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer | ||
| NCT00365183 | Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer | ||
| NCT00734773 | Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL | ||
| NCT01980654 | Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma | ||
| NCT00080028 | Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer | ||
| NCT01543763 | Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors |
